Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death 3. The Job Market for 2008-2009: Compensation 4. Renal Artery Stenosis 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesDistinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction
European Heart Journal, 06/05/09
Hamdani N et al. – Myocardial effects unique to either heart failure (HF) with normal left ventricular ejection fraction (LVEF) (HFNEF) or HF with reduced LVEF (HFREF) may contribute to the dissimilar outcome of beta-blocker therapy in both HF phenotypes.
Methods- Study of whether beta-blockers have distinct myocardial effects in HFNEF and HFREF, myocardial structure, cardiomyocyte function, and myocardial protein composition in HFNEF and HFREF pts with/without beta-blockers free of coronary artery disease
- Pt classification: 16 beta-HFNEF, 16 beta+HFNEF, 17 beta-HFREF, 22 beta+HFREF
- LV endomyocardial biopsies for collagen volume fraction (CVF) and cardiomyocyte diameter (MyD) by histomorphometry, phosphorylation of myofilamentary proteins by ProQ-Diamond phosphostained 1D-gels, and expression of beta-adrenergic signalling and calcium handling proteins by western immunoblotting
- Cardiomyocytes isolated from biopsies to measure active force (Factive), resting force (Fpassive), and calcium sensitivity (pCa50)
- Myocardial effects of beta-blocker therapy either shared by HFNEF and HFREF, unique to HFNEF or unique to HFREF
- Shared: higher Factive, higher pCa50, lower phosphorylation of troponin I and myosin-binding protein C, and lower beta-2 adrenergic receptor expression
- Unique to HFNEF: higher Fpassive, lower CVF, lower MyD, and lower expression of stimulatory G protein
- Unique to HFREF: lower expression of inhibitory G protein
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
New Anticoagulants for Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 09/15/09
Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)
The American Journal of Cardiology, 11/05/09
Today in Heart Failure...keeping you current
Receive free subspecialty "5-minute updates" via email
Obesity-Related Cardiorenal Syndrome
The Journal of Clinical Hypertension, 10/20/09
The Atrial Fibrillation Paradox of Heart Failure
Congestive Heart Failure, 09/29/09
Prognosis in Heart Failure and the Value of Beta-blockers are Altered by the Use of Antidepressants and Depend on the Type of Antidepressants Used
Circulation: Heart Failure, 09/24/09
Today in Myocardium/Pericardium...keeping you current
Receive free subspecialty "5-minute updates" via email
Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study
The Lancet Neurology, 10/16/09
Prediction of 30-Day Mortality in Older Patients with a First Acute Myocardial Infarction
Cardiology, 10/12/09
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial
European Heart Journal, 10/27/09
Today in Physiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Obesity-Related Cardiorenal Syndrome
The Journal of Clinical Hypertension, 10/20/09
Usefulness of Various Plasma Biomarkers for Diagnosis of Heart Failure in Children With Single Ventricle Physiology
The American Journal of Cardiology, 10/27/09
The Effects of Resistance Training on Metabolic Health With Weight Regain
The Journal of Clinical Hypertension, 11/04/09
Sponsor
Article Search
Sponsor
Sponsor